I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Safety and Efficacy of Lebrikizumab in Adolescent Patients ..:
Amy S. Paller
;
Carsten Flohr
;
Lawrence F. Eichenfield
...
https://doi.org/10.1007/s13555-023-00942-y. , 2023
Link:
https://doi.org/10.1007/s13555-023-00942-y
RT Journal T1
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:f1994888427840c4b87a98813eff0651&Exemplar=1&LAN=DE A1 Amy S. Paller A1 Carsten Flohr A1 Lawrence F. Eichenfield A1 Alan D. Irvine A1 Jamie Weisman A1 Jennifer Soung A1 Ana Pinto Correia A1 Chitra R. Natalie A1 Claudia Rodriguez Capriles A1 Evangeline Pierce A1 Sarah Reifeis A1 Renata Gontijo Lima A1 Clara Armengol Tubau A1 Vivian Laquer A1 Stephan Weidinger PB Adis, Springer Healthcare YR 2023 K1 Adolescents K1 Efficacy K1 IL-13 K1 Lebrikizumab K1 Moderate-to-severe atopic dermatitis K1 Safety K1 Dermatology K1 RL1-803 JF https://doi.org/10.1007/s13555-023-00942-y LK http://dx.doi.org/https://doi.org/10.1007/s13555-023-00942-y DO https://doi.org/10.1007/s13555-023-00942-y SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)